Datar Cancer Genetics Launches AI Platform for Personalised Cancer Treatment

Datar Cancer Genetics (DCG), a Maharashtra-based diagnostic centre, has introduced Exacta AI, an AI-powered multi-analyte platform designed to optimise treatment options for cancer patients. The platform integrates molecular, proteomic, genomic, functional, and clinical data, using AI-assisted analysis to generate personalised treatment strategies. 

It also evaluates drug synergy, interactions, toxicity, and contraindications for a wide range of therapies, including antibody-drug conjugates (ADCs), checkpoint inhibitors (CPIs), targeted therapies, endocrine agents, chemotherapy, and repurposed drugs. 

Exacta AI can propose up to 10 evidence-based multi-drug combinations for oncologists and molecular tumour boards (MTBs) to consider.

“This AI-powered approach is poised to provide an integrated, evidence-based set of treatment options that can transform how we personalise cancer treatment,” said Dr Sewanti Limaye, director of medical and precision oncology at Sir HN Reliance Foundation Hospital.

Dr Darshana Patil, senior director for global strategy and medical affairs at DCG, also highlighted the platform’s role in handling large volumes of clinical and molecular data. “When standard treatments fail, oncologists and MTBs must analyse massive datasets while racing against time to make critical decisions. Exacta AI transforms this challenge into an opportunity for personalised medicine.”

The AI-driven system also enhances MTB workflows by presenting structured case analyses, evidence-based treatment options, and references to similar reported cases. 

In a retrospective study of 265 patients with drug-resistant solid organ cancers, Exacta AI provided at least seven therapy options per patient. In contrast, conventional molecular profiling yielded only two options for 15% of patients.

Dr Vineet Datta, senior director for global strategy and business development at DCG, explained that Exacta AI functions like a multidisciplinary expert team, which processes data in minutes instead of days.

Exacta AI is now available for cancer centres and hospitals, with seamless integration, training, and ongoing support.

Regarding the use of AI in medicine and its advantages, Dr Andy Gaya, a clinical oncologist at The Cromwell Hospital in London, said that technology provides an unprecedented level of therapy analysis. It aims to improve patient outcomes while reducing exposure to ineffective treatments.

When looking at beating cancer with genomics and AI, an Infosys-backed Bengaluru startup, 4baseCare, introduced a similar approach to treating oncology patients in India. 

In an interaction with AIM, co-founder and CEO of 4baseCare, Hitesh Goswami, explained that today lung cancer stage-2 and stage-3 patients are subgrouped into 12-15 categories. Each category requires distinct treatments, as therapies effective for one group may not work for another and could even cause adverse reactions.

This calls for even more attention to customised treatments for patients rather than standardised procedures to be applied uniformly.